ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from ...

FMDQ Group Plc has commemorated the 8th edition of its prestigious GOLD Awards, continuing its long-standing tradition of ...

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...

In a second poster, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat ...

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...

Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...

There's a kaleidoscope of copyright cases aimed at setting boundaries on what AI companies can and can't do with human-produced creative work. Like with other decisions, a recent ruling in Getty's AI ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.